X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9815) 9815
Newsletter (55) 55
Magazine Article (24) 24
Book Chapter (12) 12
Dissertation (4) 4
Newspaper Article (4) 4
Conference Proceeding (2) 2
Book / eBook (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7793) 7793
triazoles - therapeutic use (6149) 6149
female (4471) 4471
male (3500) 3500
middle aged (2536) 2536
triazoles - pharmacology (2314) 2314
antifungal agents - therapeutic use (2247) 2247
animals (2229) 2229
adult (2214) 2214
pharmacology & pharmacy (1986) 1986
voriconazole (1803) 1803
triazoles - administration & dosage (1747) 1747
treatment outcome (1722) 1722
nitriles - therapeutic use (1629) 1629
aged (1580) 1580
triazoles - adverse effects (1443) 1443
oncology (1396) 1396
breast neoplasms - drug therapy (1345) 1345
pyrimidines - therapeutic use (1260) 1260
triazoles (1168) 1168
mice (999) 999
microbiology (960) 960
infectious diseases (905) 905
therapy (794) 794
breast cancer (777) 777
care and treatment (774) 774
triazoles - pharmacokinetics (741) 741
cancer (711) 711
analysis (710) 710
aromatase inhibitors - therapeutic use (705) 705
drug therapy, combination (699) 699
adolescent (692) 692
antineoplastic agents, hormonal - therapeutic use (677) 677
letrozole (672) 672
aromatase inhibitors (650) 650
triazoles - chemistry (636) 636
antifungal agents - pharmacology (635) 635
drug therapy (633) 633
rats (631) 631
tamoxifen (624) 624
health aspects (622) 622
antifungal agents (614) 614
dose-response relationship, drug (602) 602
anastrozole (597) 597
antifungal agents - administration & dosage (592) 592
pharmacokinetics (586) 586
amphotericin b - therapeutic use (573) 573
tamoxifen - therapeutic use (573) 573
efficacy (571) 571
sitagliptin phosphate (570) 570
fluconazole (568) 568
research (568) 568
postmenopausal women (562) 562
aspergillosis - drug therapy (554) 554
antineoplastic agents - therapeutic use (553) 553
mycoses - drug therapy (549) 549
amphotericin-b (528) 528
safety (527) 527
young adult (523) 523
itraconazole (521) 521
medicine & public health (518) 518
microbial sensitivity tests (517) 517
posaconazole (517) 517
breast neoplasms - pathology (510) 510
aged, 80 and over (508) 508
postmenopause (506) 506
double-blind method (504) 504
nitriles - administration & dosage (504) 504
chemistry, medicinal (499) 499
immunology (489) 489
hematology (460) 460
pyrazines - therapeutic use (458) 458
double-blind (455) 455
aspergillosis (452) 452
child (451) 451
administration, oral (450) 450
retrospective studies (441) 441
biochemistry & molecular biology (431) 431
diabetes mellitus, type 2 - drug therapy (429) 429
time factors (415) 415
mycoses (412) 412
antineoplastic combined chemotherapy protocols - therapeutic use (410) 410
medicine, general & internal (402) 402
disease models, animal (399) 399
internal medicine (399) 399
benzoates - therapeutic use (393) 393
cell line, tumor (393) 393
antifungal agents - adverse effects (392) 392
nitriles - adverse effects (392) 392
clinical trials as topic (385) 385
pyrimidines - pharmacology (380) 380
infections (376) 376
endocrinology & metabolism (375) 375
drug interactions (372) 372
chemotherapy (371) 371
pharmacology (365) 365
in-vitro (364) 364
randomized controlled trials as topic (362) 362
antifungal agents - pharmacokinetics (361) 361
triazole (360) 360
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9412) 9412
Japanese (144) 144
German (128) 128
Spanish (99) 99
French (89) 89
Chinese (40) 40
Italian (35) 35
Russian (32) 32
Hungarian (15) 15
Turkish (10) 10
Polish (9) 9
Dutch (8) 8
Portuguese (6) 6
Ukrainian (6) 6
Czech (4) 4
Danish (3) 3
Romanian (3) 3
Swedish (2) 2
Hebrew (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
Diabetes and Metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
...% of early breast cancers, are unknown. 7 The combination of ovarian suppression with the use of gonadotropin-releasing hormone analogues and tamoxifen is a standard... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Best Practice & Research: Clinical Obstetrics & Gynaecology, ISSN 1521-6934, 2016, Volume 37, pp. 152 - 159
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 631 - 641
Journal Article